|
業務類別
|
Biotechnology |
|
業務概覽
|
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support,or PS, which includes both nutrition and fluids. |
| 公司地址
| 345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010 |
| 電話號碼
| +1 646 844-0337 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.protaratx.com |
| 員工數量
| 51 |
| Ms. Jacqueline Zummo, M.B.A.,M.P.H.,PhD |
Chief Research and Development Officer |
美元 494.00K |
28/04/2026 |
| Mr. Jesse Shefferman, PhD |
Chief Executive Officer, President and Director |
美元 654.89K |
28/04/2026 |
| Ms. Hannah Fry |
Controller and Principal Accounting Officer |
-- |
28/04/2026 |
| Mr. Patrick Fabbio |
Chief Financial Officer |
-- |
28/04/2026 |
| Mr. William Conkling |
Chief Commercial Officer |
-- |
28/04/2026 |
|
|
| Dr. Richard S. Levy,M.D. |
Independent Director |
28/04/2026 |
| Mr. Jesse Shefferman, PhD |
Chief Executive Officer, President and Director |
28/04/2026 |
| Dr. Jane Huang, M.D. |
Independent Director |
28/04/2026 |
| Mr. Barry P. Flannelly, Pharm.D. |
Independent Director |
28/04/2026 |
| Ms. Cynthia Smith |
Independent Director |
28/04/2026 |
| Dr. Roger J. Garceau,M.D.,F.A.A.P. |
Independent Director |
28/04/2026 |
| Dr. Michael Edward Solomon, PhD |
Independent Director |
28/04/2026 |
| Mr. Luke M. Beshar |
Chairman of the Board |
28/04/2026 |
| Mr. Gregory P. Sargen |
Independent Director |
28/04/2026 |
|
|
|
|
